» Articles » PMID: 28666009

Delivery of Gene Targeting SiRNAs to Breast Cancer Cells Using a Multifunctional Peptide Complex That Promotes Both Targeted Delivery and Endosomal Release

Overview
Journal PLoS One
Date 2017 Jul 1
PMID 28666009
Citations 11
Authors
Affiliations
Soon will be listed here.
Abstract

RNA interference has been used to dissect the importance of individual gene products in various human disease processes, including cancer. Small-interfering RNA, or siRNA, is one of the tools utilized in this regard, but specially-designed delivery agents are required to allow the siRNA to gain optimal access to the cell interior. Our laboratory has utilized two different siRNA-binding delivery peptides containing a polyarginine core, and modified by myristoylation and targeting motifs (iRGD or Lyp-1). A third peptide was designed to assist with endosomal release. Various ratios of the peptides and siRNA were combined and assayed for the ability to form stable complexes, and optimized ratios were determined. The complexes were found to form particles, with the majority having a diameter of 100-300 nm, as visualized by electron microscopy. These siRNA complexes have enhanced protection from nucleases present in serum, as compared to "naked" unprotected siRNA. The particles were internalized by the cells and could be detected in the cell cytoplasm by confocal fluorescence microscopy. In functional assays, peptide/siRNA complexes were shown to cause the knock down of corresponding targeted proteins. The peptide with the LyP-1 targeting motif was more effective at knockdown in MDA-MB-231 breast cancer cells than the peptide with the iRGD motif. Inclusion of the endosomal release peptide in the complexes greatly enhanced the peptide/siRNA effects. Peptide/siRNA complexes simultaneously targeting Stat3 and c-Myc caused a marked reduction in anchorage-independent growth, a property correlated with tumorigenicity. This study demonstrates the ability of a peptide-based siRNA-delivery system to deliver siRNA into breast cancer cells and cause both protein knockdown and suppression of the malignant phenotype. Such peptide complexes are likely to become highly useful siRNA-delivery vehicles for the characterization, and potentially for the treatment, of human cancer.

Citing Articles

Nucleic acid drugs: recent progress and future perspectives.

Sun X, Setrerrahmane S, Li C, Hu J, Xu H Signal Transduct Target Ther. 2024; 9(1):316.

PMID: 39609384 PMC: 11604671. DOI: 10.1038/s41392-024-02035-4.


Development of hyaluronic acid-anchored polycaprolactone nanoparticles for efficient delivery of PLK1 siRNA to breast cancer.

Jain D, Yadav A Drug Deliv Transl Res. 2023; 13(6):1730-1744.

PMID: 36641487 DOI: 10.1007/s13346-022-01288-2.


Membrane Internalization Mechanisms and Design Strategies of Arginine-Rich Cell-Penetrating Peptides.

Hao M, Zhang L, Chen P Int J Mol Sci. 2022; 23(16).

PMID: 36012300 PMC: 9409441. DOI: 10.3390/ijms23169038.


Characterization and targeting ability evaluation of cell-penetrating peptide LyP-1 modified alginate-based nanoparticles.

Zhong Z, Cai L, Li C RSC Adv. 2022; 10(54):32443-32449.

PMID: 35516495 PMC: 9056619. DOI: 10.1039/d0ra06628a.


Development of iRGD-Modified Peptide Carriers for Suicide Gene Therapy of Uterine Leiomyoma.

Egorova A, Shtykalova S, Selutin A, Shved N, Maretina M, Selkov S Pharmaceutics. 2021; 13(2).

PMID: 33540912 PMC: 7913275. DOI: 10.3390/pharmaceutics13020202.


References
1.
Ku S, Kim K, Choi K, Kim S, Kwon I . Tumor-targeting multifunctional nanoparticles for siRNA delivery: recent advances in cancer therapy. Adv Healthc Mater. 2014; 3(8):1182-93. DOI: 10.1002/adhm.201300607. View

2.
Mansoori B, Sandoghchian Shotorbani S, Baradaran B . RNA interference and its role in cancer therapy. Adv Pharm Bull. 2014; 4(4):313-21. PMC: 4137419. DOI: 10.5681/apb.2014.046. View

3.
Soker S, Takashima S, Miao H, Neufeld G, Klagsbrun M . Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor. Cell. 1998; 92(6):735-45. DOI: 10.1016/s0092-8674(00)81402-6. View

4.
Wang J, Lu Z, Wientjes M, Au J . Delivery of siRNA therapeutics: barriers and carriers. AAPS J. 2010; 12(4):492-503. PMC: 2977003. DOI: 10.1208/s12248-010-9210-4. View

5.
Li Y, Li Y, Wang X, Lee R, Teng L . Fatty acid modified octa-arginine for delivery of siRNA. Int J Pharm. 2015; 495(1):527-535. DOI: 10.1016/j.ijpharm.2015.09.006. View